Skip to Content
Merck
All Photos(1)

Key Documents

1019508

USP

Amikacin

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H43N5O13
CAS Number:
37517-28-5
Molecular Weight:
585.60
EC Number:
253-538-5
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

amikacin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1

InChI key

LKCWBDHBTVXHDL-RMDFUYIESA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Amikacin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Amikacin Sulfate
  • Amikacin Sulfate Injection
  • Kanamycin Injection
  • Kanamycin Sulfate

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317

Hazard Classifications

Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Bruce Montgomery et al.
Antimicrobial agents and chemotherapy, 58(7), 3714-3719 (2014-04-23)
The amikacin-fosfomycin inhalation system (AFIS) is a combination of 2 antibiotics and an in-line nebulizer delivery system that is being developed for adjunctive treatment of pneumonia caused by Gram-negative organisms in patients on mechanical ventilation. AFIS consists of a combination
Wenjuan Nie et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 25, 170-174 (2014-06-17)
To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp. abscessus using species identification, and to investigate the in vitro activity of amikacin, cefoxitin, imipenem, levofloxacin, moxifloxacin, clarithromycin, azithromycin, and linezolid against Mycobacterium abscessus. Seventy M. abscessus isolates, previously identified
Monika E Łysakowska et al.
Burns : journal of the International Society for Burn Injuries, 41(2), 364-371 (2014-08-26)
Acinetobacter baumannii isolates are responsible for a high number of wound infections. The reason of this study was to evaluate the activity of silver nanoparticles obtained by microexplosion against wide range of Acinetobacter spp. Susceptibility to silver nanoparticles was tested
Ming Zhang et al.
Antimicrobial agents and chemotherapy, 58(6), 3217-3223 (2014-03-26)
Oxazolidinones represent a new class of antituberculosis drugs that exert their function by inhibiting protein synthesis. Here, we compared the activities of three oxazolidinones, linezolid, PNU-100480, and AZD5847, against latent tuberculosis using a simple model employing the streptomycin-starved Mycobacterium tuberculosis
Sasha J Rose et al.
PloS one, 9(9), e108703-e108703 (2014-09-30)
Pulmonary infections caused by nontuberculous mycobacteria (NTM) are an increasing problem in individuals with chronic lung conditions and current therapies are lacking. We investigated the activity of liposomal amikacin for inhalation (LAI) against NTM in vitro as well as in
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service